July 22 (Reuters) - UK's MHRA:
MHRA: RECEIVED REPORTS DESCRIBING POSITIVE BIAS IN HBA1C RESULTS DELIVERED BY TRINITY BIOTECH PREMIER HB9210 HBA1C ANALYSER
MHRA: POSITIVE BIAS IN HBA1C RESULTS RESULTED IN PATIENTS BEING INCORRECTLY DIAGNOSED AS PRE-DIABETIC OR DIABETIC.
MHRA: TRINITY BIOTECH COMMITTED TO UPDATING INTENDED USE STATEMENT IN THE INSTRUCTIONS FOR USE
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.